INVESTMENTS THAT MATTER

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

Across all stages of development, we align ourselves with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations that will have a positive impact on patients’ lives.

OUR PROVEN STRATEGY

At Agent Capital, we proactively guide biotech companies to milestones and exits.

With a balanced investment approach and a deep understanding of biopharma’s pipeline pressures, we are committed to making investments that move healthcare forward – no matter the stage or investment type.

TYPICALLY, OUR KEY INVESTMENT AREAS OF FOCUS INCLUDE:

Rare Diseases
Oncology
Neurology
Immunology
Learn More

Featured Portfolio Company

Skyhawk Therapeutics

Carisma Therapeutics

Entrada Therapeutics

Pliant Therapeutics

Pyxis Oncology

Dragonfly Therapeutics

Freenome

ImCheck Therapeutics

Seed: Mediar Therapeutics

Dice Molecules

Orbus Therapeutics

View Full Portfolio

Featured News

Press Release | March 31, 2021

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

Read More

Press Release | March 30, 2021

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

Read More

Press Release | March 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

Read More

View All